Merck inks Keytruda supply pact to support Exelixis cancer trial

IlluminaIllumina stock (US4523271090): Corporate Responsibility Report highlights genomics growth drivers - AD HOC NEWS

Eli LillyElil Lilly buys a Bay Area Y Combinator alum for up to $202M - The Business Journals

PfizerPharma sector doubles down on AI amid hopes of slashing costs, timelines - Reuters

FierceBiotechGHO Capital, CBC Group plan to merge, forming $21B healthcare investment firm

Eli LillyEli Lilly Acquires Engage Bio | PharmExec - Pharmaceutical Executive

Mettler ToledoMettler-Toledo stock (US5926881054): analysts’ targets and earnings keep focus on precision instru - AD HOC NEWS

LabCorpLabcorp Launches AI-Powered App to Help Patients Understand Test Results - Clinical Lab Products

RevvityRevvity Inc. stock (US76155R1086): investors weigh latest earnings and diagnostics focus - AD HOC NEWS

Eli LillyCollaborative Drug Discovery Inks Deal with Eli Lilly to Accelerate Biotech Innovation - Genetic Engineering and Biotechnology News

Clinical OMICsEarly Medical Care Linked to Rapid Gut Microbiome Shifts in Amazonian Indigenous Communities

Clinical OMICsAI Shows Value for Breast Cancer Prediction

Merck & Co.EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study - TradingView